Back to top
more

Merck & Co. (MRK)

(Delayed Data from NYSE)

$109.77 USD

109.77
9,704,771

-0.41 (-0.37%)

Updated Oct 4, 2024 04:00 PM ET

After-Market: $109.53 -0.24 (-0.22%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value C Growth D Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 19% (47 out of 252)

Industry: Large Cap Pharmaceuticals

Better trading starts here.

Zacks News

Stock Market News for Oct 4, 2024

U.S. stock markets closed lower on Thursday after a choppy session.

Merck (MRK) Dips More Than Broader Market: What You Should Know

Merck (MRK) concluded the recent trading session at $110.18, signifying a -1.7% move from its prior day's close.

Will Merck (MRK) Beat Estimates Again in Its Next Earnings Report?

Merck (MRK) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

How to Find Strong Medical Stocks Slated for Positive Earnings Surprises

Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.

Kinjel Shah headshot

Pharma Stock Roundup: JNJ's 3rd Talc-Related Bankruptcy Filing & More

JNJ files for voluntary bankruptcy for the third time. Pfizer withdraws sickle-cell drug drug Oxbryta from worldwide markets.

Merck (MRK) Stock Sinks As Market Gains: Here's Why

In the latest trading session, Merck (MRK) closed at $113.09, marking a -1.43% move from the previous day.

MRK's Keytruda Combo Fails in Phase III Colorectal Cancer Study

The phase III KEYFORM-007 study, evaluating Merck's Keytruda plus favezelimab for treating metastatic colorectal cancer, fails to meet the primary endpoint.

AZN Stock Slips as Dato-DXd Cancer Study Misses Survival Goal

AZN's Daiichi Sankyo-partnered datopotamab deruxtecan fails to show overall survival benefits in a breast cancer study. Stock falls.

Company News for Sep 24, 2024

Companies in The News Are: TSLA, DPZ, INTC, APO, MRK

EMA Committee Endorses AbbVie's Elahere in Ovarian Cancer

If approved, this will be the first regulatory approval for ABBV's Elahere in the European Union.

MRK Gets Positive CHMP Nod for Keytruda in Two Gynecologic Cancers

The Committee for Medicinal Products for Human Use recommends marketing approval for Merck's Keytruda for treating two types of gynecologic cancers.

Merck (MRK) Stock Moves -0.05%: What You Should Know

Merck (MRK) reachead $117.17 at the closing of the latest trading day, reflecting a -0.05% change compared to its last close.

Kinjel Shah headshot

Pharma Stock Roundup: FDA Approvals for LLY, MRK, AZN & JNJ Drugs

FDA approves Lilly's eczema drug, Ebglyss, and the expanded use of Novartis' Kisqali, Merck's Keytruda and AstraZeneca's Fasenra.

Kinjel Shah headshot

Merck Loses Around $32B in 3 Months: Time to Sell the Stock?

Declining estimates and the recent price drop make investors skeptical about holding MRK stock.

Merck (MRK) Stock Dips While Market Gains: Key Facts

In the closing of the recent trading day, Merck (MRK) stood at $117.23, denoting a -1.19% change from the preceding trading day.

Merck's Keytruda Obtains its First FDA Approval for Mesothelioma

The FDA approves MRK's Keytruda for first-line treatment of malignant pleural mesothelioma. This marks Keytruda's first approval for the given indication.

Investors Heavily Search Merck & Co., Inc. (MRK): Here is What You Need to Know

Merck (MRK) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.

Study: Merck and Daiichi's Lung Cancer Treatment Shows Promise

MRK and Daiichi Sankyo's patritumab deruxtecan shows statistically significant progression-free survival improvement in previously treated EGFR-mutated NSCLC.

Is It Worth Investing in Merck (MRK) Based on Wall Street's Bullish Views?

According to the average brokerage recommendation (ABR), one should invest in Merck (MRK). It is debatable whether this highly sought-after metric is effective because Wall Street analysts' recommendations tend to be overly optimistic. Would it be worth investing in the stock?

NuCana Stock Soars 151% on Upbeat Efficacy Data From Melanoma Study

NCNA stock surges 151% on positive efficacy data from the mid-stage melanoma study of NUC-7738 in combination with Merck's Keytruda.

Instil Bio Stock Skyrockets 641% in One Week: Here's Why

A rival posted encouraging data on a drug that outperformed Keytruda in certain NSCLC patients. TIL licenses a drug candidate that uses a similar mechanism.

Merck (MRK) Increases Yet Falls Behind Market: What Investors Need to Know

In the most recent trading session, Merck (MRK) closed at $115.86, indicating a +0.53% shift from the previous trading day.

MRNA Stock Falls 12% on Lowered Sales Outlook, R&D Budget Cuts

As part of its strategic prioritization, Moderna aims to cut its R&D expenses by 20% over the next four years. It decides to end five pipeline programs to save costs.

Here's Why Merck (MRK) Gained But Lagged the Market Today

Merck (MRK) closed at $115.25 in the latest trading session, marking a +0.47% move from the prior day.

Bristol Myers Stock Rises 16% in 3 Months: Buy, Sell or Hold?

BMY's recent rally gives investors a ray of hope after the downturn earlier on in 2024. However, we advise investors not to be over-optimistic at this point and look before they leap.